The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Benefit of EGFR-inhibition therapy for metastatic colorectal cancer patients with KRAS-mutated tumors and high plasma TIMP-1 level: Results from the NORDIC VII study.
Nils Brunner
No relevant relationships to disclose
Line Schmidt Tarpgaard
No relevant relationships to disclose
Ib Jarle Christensen
No relevant relationships to disclose
Jose Moreira
No relevant relationships to disclose
Tormod Kyrre Guren
No relevant relationships to disclose
Bengt Glimelius
No relevant relationships to disclose
Halfdan Sorby
No relevant relationships to disclose
Tone Ikdahl
No relevant relationships to disclose
Elin Kure
No relevant relationships to disclose
Kjell Magne Tveit
No relevant relationships to disclose
Hans Jørgen Nielsen
No relevant relationships to disclose
Per Pfeiffer
No relevant relationships to disclose